-
3 Two Hospital Networks and a Portable Molecular Testing Maker Stocks With a Strong Future Roadmap: Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics
- October 21, 2026
- Posted by: Chaitanya Auti
- Category: Best Stocks
No Comments
Hospital and Molecular Testing Stocks with a strong future roadmap: Fortis Healthcare, Max Healthcare Institute and Molbio Diagnostics. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Metro Lab Network, Wellness Testing and Rapid Molecular Kits Stocks With a Strong Future Roadmap: Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics
- October 21, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Pathology and Testing Stocks with a strong future roadmap: Dr. Lal PathLabs, Thyrocare Technologies and Molbio Diagnostics. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Tertiary Hospital, Paediatric Care and Molecular Diagnostics Stocks With a Strong Future Roadmap: Global Health, Rainbow Children’s Medicare and Molbio Diagnostics
- October 21, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Specialty Healthcare Stocks with a strong future roadmap: Global Health, Rainbow Children’s Medicare and Molbio Diagnostics. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
Molbio Diagnostics Share Price Target Rs 1,600: Stock Jumps 5% as HDFC Mutual Fund Buys 1.99% in Bulk Deal
- October 1, 2026
- Posted by: Lakshit Sharma
- Category: News
Molbio Diagnostics share price rose over 5% as HDFC Mutual Fund bought a 1.99% stake. Here is the bulk deal, the Jefferies Rs 1,600 target and the risks.